<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813735</url>
  </required_header>
  <id_info>
    <org_study_id>ESRCO66</org_study_id>
    <nct_id>NCT00813735</nct_id>
  </id_info>
  <brief_title>Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder</brief_title>
  <official_title>Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lehigh Center for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lehigh Center for Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research has established the incidence of insomnia increases with age and the possible causes
      contributing to sleep problems in the elderly are still being explored and debated. Older
      adults use a disproportionately large share of sleep aids with non-prescription sleep aid use
      having increased over the past decade. This study is a double blind safety and effectiveness
      trial examining the response of eszopiclone co-administered with escitalopram for the
      treatment of insomnia symptoms in geriatric depressed adults with insomnia symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, parallel-group study. There are two
      groups of subjects with Major Depressive Disorder and insomnia symptoms randomized to
      treatment either with eszopicone 2mg or placebo daily at bedtime for 14 weeks beginning at
      visit 2. Also, all subjects receive open label treatment with escitalopram 10 or 20mg daily
      in the morning. Safety and efficacy is evaluated as well as rating scales and patient sleep
      diaries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total sleep time from baseline to final visit</measure>
    <time_frame>from baseline to final visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in sleep latency from baseline to final visit</measure>
    <time_frame>from baseline to final visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAMD from baseline to final visit</measure>
    <time_frame>from baseline to final visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ISI from baseline to final visit</measure>
    <time_frame>baseline to final visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-S, CGI-I from baseline to final visit</measure>
    <time_frame>baseline to final visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>labs (CBC,urinalysis,TSH,Chemprofile,drugscreen),height</measure>
    <time_frame>visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vitals: BP,pulse,temperature,weight,assess AE's/SAE's</measure>
    <time_frame>every visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo, Drug: Escitalopram 10mg or 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>Eszopiclone 2mg daily at bedtime</description>
    <arm_group_label>Eszopiclone</arm_group_label>
    <other_name>Escitalopram 10mg or 20mg daily in the AM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily at bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Escitalopram 10mg or 20mg daily in the AM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram 10mg or 20mg</description>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MDD, HAMD score 20 or greater at screening and baseline, total sleep time
             less than 6 hours at screening and baseline, ISI 15 or greater at screening and
             baseline

        Exclusion Criteria:

          -  May not use any other psychoactive drugs/psychotropics during study, may not have any
             type of dementia, may not have any significant/unstable medical problems, no
             nightshift work permitted, no current seizure disorders/head injuries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul K Gross</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehigh Center for Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lehigh Center for Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Major Depression</keyword>
  <keyword>Geriatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 8, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>September 9, 2014</submitted>
    <returned>September 12, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

